Table 1 Baseline patient characteristics.

From: Nebulized enriched heparin improves respiratory parameters in patients with COVID-19: a phase I/II randomized and triple-blind clinical trial

Characteristics

Placebo (n = 14)

Heparin (n = 13)

P value

Age (years)

55 (16.1)

50 (12.6)

0.3788*

Height (cm)

167 (11.2)

162.92 (12)

0.3702*

Weight (kg)

90.57 (16.7)

79.85 (24.1)

0.1884*

BMI (kg/m2)

32.80 (7.4)

29.62 (7.3)

0.2712*

Days of symptoms

12 (5.75)

10 (4)

0.3508**

Vaccinated (2nd dose)

0 (0)

0 (0)

0.9999#

Gender

  

0.4495#

Male

8 (57.1)

5 (38.5)

 

Women

6 (42.9)

8 (61.5)

 

Ethnicity

  

0.4815#

White

12 (85.7)

13 (100)

 

Black

2 (14.3)

0 (0)

 

Behavioural factors

Sedentary lifestyle

12 (85.7)

10 (76.9)

0.6483#

Smoking

1 (7.1)

2 (15.4)

0.5956#

Ex-smoking

2 (14.3)

4 (30.8)

0.3845#

Alcoholism

0 (0)

2 (15.4)

0.2222#

Comorbidity

Systemic arterial hypertension

9 (64.3)

6 (46.2)

0.4495#

Coronary heart disease

2 (14.3)

2 (15.4)

0.9999#

Non-coronary heart disease

2 (14.3)

1 (7.7)

0.9999#

Dyslipidaemia

5 (35.7)

10 (76.9)

0.0542#

Cerebrovascular ischemic events

1 (7.1)

1 (7.7)

0.9999#

Neoplasm

0 (0)

0 (0)

0.9999#

Kidney transplant or immunosuppression

3 (21.4)

3 (23.1)

0.9999#

Autoimmune disease

0 (0)

1 (7.7)

0.4815#

Pneumopathy

1 (7.1)

2 (15.4)

0.5956#

Hypothyroidism

0 (0)

2 (15.4)

0.2222#

Depression

2 (14.3)

0 (0)

0.4815#

Concomitant antibiotics

5 (35.7)

5 (38.5)

0.9999#

Ceftriaxone 2000 mg/d

1 (7.1)

3 (23.1)

0.3259#

Azithromycin 500 mg/d

1 (7.1)

0 (0)

0.9999#

Cefepime 6000 mg/d

2 (14.3)

0 (0)

0.4815#

Amoxicillin + Clavulanate 1500 + 300 mg/d

1 (7.1)

2 (15.4)

0.5956#

Concomitant Dexamethasone 6 mg IV/d

14 (100)

11 (84.6)

0.2222#

  1. *Unpaired t test / results expressed as mean (standard deviation).
  2. **Mann–Whitney test / results expressed as median (IQR).
  3. #Fisher's exact test / results expressed as n (%).